Clinical Trial Update: Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Bevacizumab was studied in a Phase 2 trial for relapsed or refractory multiple myeloma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Mayo Clinic | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED